Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of FXS6837 Versus Eculizumab in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT07747090 is registered in ClinicalTrials.gov with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. as lead sponsor.

NCT NCT07747090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07747090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of FXS6837 Versus Eculizumab in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Lead sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 10, 2026
Completion date
July 31, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria